An educated thought is that you personally would be estimating the effectiveness of stem call treatment higher if it was multistem being used in the trial.
But yes, with mortality rates being lower overall, there's a reasonable chance what your saying could occur.
- Forums
- ASX - By Stock
- MSB
- COVID ARDS interim analysis
MSB
mesoblast limited
Add to My Watchlist
1.80%
!
$1.70

COVID ARDS interim analysis, page-2
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.70 |
Change
0.030(1.80%) |
Mkt cap ! $2.175B |
Open | High | Low | Value | Volume |
$1.67 | $1.74 | $1.67 | $6.647M | 3.897M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 44280 | $1.69 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.70 | 26847 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 983 | 1.750 |
1 | 15000 | 1.740 |
2 | 1001 | 1.730 |
1 | 2454 | 1.710 |
1 | 215 | 1.700 |
Price($) | Vol. | No. |
---|---|---|
1.615 | 14363 | 3 |
1.675 | 187 | 1 |
1.690 | 3500 | 2 |
1.700 | 9612 | 2 |
1.715 | 5539 | 1 |
Last trade - 16.10pm 15/07/2025 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
HAR
HARANGA RESOURCES LIMITED.
Peter Batten, MD
Peter Batten
MD
Previous Video
Next Video
SPONSORED BY The Market Online